World-first clinical trials begin for promising new anti-clotting stroke drug
HRI has made a breakthrough 25 years in the making, identifying and developing a new anti-clotting drug that shows great promise in the treatment of stroke.
NAIDOC Week at HRI: For our Elders
This year during NAIDOC Week, HRI took the opportunity to learn about First Nations cultures and histories, and to celebrate the oldest, continuous living cultures on earth.
World first: risk of dementia linked to high cholesterol
HRI has made a world-first breakthrough discovery, linking high cholesterol with an increased risk of dementia for the first time.
Pioneering cardiovascular disease research enabling personalised medical treatment
HRI is using innovative fluxomics technology to identify and explore the cell molecular fingerprint unique to each person's cardiovascular disease, with the goal of personalised medicine.
Is it possible to restore circulation in someone with peripheral artery disease?
PhD student Manisha Patil presented the latest research on new avenues to treat peripheral artery disease at the European Society for Microcirculation.
How a pain in your leg could be just as fatal as a pain in your chest
Assoc Prof Mary Kavurma is raising awareness of peripheral artery disease, which is now affecting more women than men and also has greater risk of amputation and cardiovascular mortality.
Dr Sergey Tumanov awarded grant by The Ian Potter Foundation for Australia’s first Fluxomics Centre
HRI's Dr Sergey Tumanov has been awarded a prestigious grant by The Ian Potter Foundation to help establish Australia’s first Fluxomics Centre devoted to cardiovascular disease.
New strategy to prevent cardiovascular disease hidden in toxic waste product
Research shows bilirubin, formerly viewed as only a toxic waste product in the body, could decrease the risk of cardiovascular disease.
Collaboration brings advances in therapeutic strategies for stiff heart failure
Dr Yen Chin Koay provides an update on spending six months investigating stiff heart failure in Prof Christopher Loughrey’s lab in Glasgow, Scotland.